Cited 12 times in
Effects of a combined alendronate and calcitriol agent (Maxmarvil®) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 안철우 | - |
dc.contributor.author | 이유미 | - |
dc.contributor.author | 임승길 | - |
dc.date.accessioned | 2015-06-10T12:25:26Z | - |
dc.date.available | 2015-06-10T12:25:26Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0937-941X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/109775 | - |
dc.description.abstract | INTRODUCTION: A randomized, double-blind, prospective, 24-week clinical trial was performed to evaluate the effects of a combinative agent, Maxmarvil, of calcitriol (0.5 mug) and alendronate (5 mg) on bone metabolism in postmenopausal women. METHODS: A total of 217 postmenopausal women with osteoporosis were enrolled; 199 patients were randomly assigned to one of two treatment groups (Maxmarvil group or alfacalcidol group). None of the patients were vitamin-D-deficient, as assessed by serum 25-hydroxyvitamin D (25(OH)D), nor had they received any drugs affecting bone metabolism before enrollment. Bone mineral densities (BMD) of L1-L4 and the femur were measured by dual-energy X-ray absorptiometry (DXA) at the initial assessment and after 6 months of treatment. Serum biochemical assays, including serum calcium, 24-h urinary calcium excretion, and bone turnover markers (both bone-specific alkaline phosphatase [bsALP] and urine N-telopeptide [NTx]), were performed at the baseline and after 3 and 6 months of treatment. RESULTS: In the Maxmarvil group, the BMD of the lumbar spine increased up to 2.42+/-0.5% from the baseline after 6 months (p<0.05). On the other hand, the change in BMD in the alfacalcidol group was 0.28+/-0.5% after 6 months. There was no significant difference in femoral BMD between the two groups. The levels of bsALP and NTx were significantly lower in the Maxmarvil group than in the alfacalcidol group (-22.04+/-3.9% vs. -11.42+/-2.8% [p<0.05] and -25.46+/-5.2% vs. 1.24+/-6.2% [p<0.001], respectively). Interestingly, there was a significantly smaller amount of 24-h urinary calcium in the Maxmarvil group (p<0.05). CONCLUSIONS: Our study demonstrates that a combination of calcitriol and alendronate is quite effective in preventing bone loss, with the advantage of lesser hypercalciuric effect of calcitriol in the postmenopausal osteoporotic women. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1801~1807 | - |
dc.relation.isPartOf | OSTEOPOROSIS INTERNATIONAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Effects of a combined alendronate and calcitriol agent (Maxmarvil®) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Y. Rhee | - |
dc.contributor.googleauthor | M. Kang | - |
dc.contributor.googleauthor | Y. Min | - |
dc.contributor.googleauthor | D. Byun | - |
dc.contributor.googleauthor | Y. Chung | - |
dc.contributor.googleauthor | C. Ahn | - |
dc.contributor.googleauthor | K. Baek | - |
dc.contributor.googleauthor | J. Mok | - |
dc.contributor.googleauthor | D. Kim | - |
dc.contributor.googleauthor | D. Kim | - |
dc.contributor.googleauthor | H. Kim | - |
dc.contributor.googleauthor | Y. Kim | - |
dc.contributor.googleauthor | S. Myoung | - |
dc.contributor.googleauthor | D. Kim | - |
dc.contributor.googleauthor | S.-K. Lim | - |
dc.identifier.doi | 10.1007/s00198-006-0200-4 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02270 | - |
dc.contributor.localId | A03012 | - |
dc.contributor.localId | A03375 | - |
dc.relation.journalcode | J02451 | - |
dc.identifier.eissn | 1433-2965 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00198-006-0200-4 | - |
dc.subject.keyword | Alendronate | - |
dc.subject.keyword | Calcitriol | - |
dc.subject.keyword | Combinative agent | - |
dc.subject.keyword | Postmenopausal osteoporosis | - |
dc.contributor.alternativeName | Ahn, Chul Woo | - |
dc.contributor.alternativeName | Rhee, Yumie | - |
dc.contributor.alternativeName | Lim, Sung Kil | - |
dc.contributor.affiliatedAuthor | Ahn, Chul Woo | - |
dc.contributor.affiliatedAuthor | Rhee, Yumie | - |
dc.contributor.affiliatedAuthor | Lim, Sung Kil | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 17 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1801 | - |
dc.citation.endPage | 1807 | - |
dc.identifier.bibliographicCitation | OSTEOPOROSIS INTERNATIONAL, Vol.17(12) : 1801-1807, 2006 | - |
dc.identifier.rimsid | 53412 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.